Larimar Therapeutics Quote - LRMR | ADVFN

S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Larimar Therapeutics Inc (LRMR) Share Price

Larimar Therapeutics Inc (LRMR)

6.16

-0.53

(-7.92%)

Closed November 18 3:00PM

Delayed by 15 minutes

6.16

0.00

(0.00%)

After Hours: 6:31PM

Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Current Price

6.16

Bid

5.98

Ask

6.25

Volume

1,119,041

5.9622 Day's Range 6.62

3.0499 52 Week Range 13.68

Market Cap

Previous Close

6.69

Open

6.53

Last Trade

Last Trade Time

Financial Volume

US$ 6,994,123

VWAP

6.2501

Average Volume (3m)

706,751

Shares Outstanding

63,806,628

Dividend Yield

-

PE Ratio

-1.71

Earnings Per Share (EPS)

-0.58

Revenue

-

Net Profit

-36.95M

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion p... Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

larimartx.com

Headquarters

Wilmington, Delaware, USA

Founded

-

Larimar Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LRMR. The last closing price for Larimar Therapeutics was US$6.69. Over the last year, Larimar Therapeutics shares have traded in a share price range of US$ 3.0499 to US$ 13.68.

Larimar Therapeutics currently has 63,806,628 shares outstanding. The market capitalization of Larimar Therapeutics is US$426.87 million. Larimar Therapeutics has a price to earnings ratio (PE ratio) of -1.71.

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-3.03	-32.9706202394	9.19	9.5	6.16	725420	8.00729067	CS
4	-1.56	-20.207253886	7.72	9.5	6.16	737256	8.0814353	CS
12	-1.78	-22.4181360202	7.94	9.5	6.07	706751	7.43319421	CS
26	-1.21	-16.4179104478	7.37	11.2	6.07	634782	7.86935983	CS
52	2.74	80.1169590643	3.42	13.68	3.0499	524134	8.21615508	CS
156	-4.51	-42.2680412371	10.67	13.68	1.53	297094	6.45634309	CS
260	-5.84	-48.6666666667	12	25.87	1.53	224078	7.22959494	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
HCWBHCW Biologics Inc	US$ 1.235 (319.21%)	509.96M
APLMApollomics Inc	US$ 0.1922 (100.42%)	1.67B
SINTSiNtx Technologies Inc	US$ 3.18 (55.88%)	51.86M
ACRSAclaris Therapeutics Inc	US$ 3.16 (54.15%)	30.55M
JWELJowell Global Ltd	US$ 2.8358 (45.43%)	15.45M
QMMMQMMM Holdings Limited	US$ 1.73 (-76.40%)	6.08M
CMAXCareMax Inc	US$ 0.87 (-48.21%)	821.72k
NGNENeurogene Inc	US$ 19.82 (-42.58%)	2M
DWTXDogwood Therapeutics Inc	US$ 1.85 (-37.71%)	138.82k
SGDSafe and Green Development Corporation	US$ 1.68 (-36.84%)	483.12k
APLMApollomics Inc	US$ 0.1922 (100.42%)	1.68B
HCWBHCW Biologics Inc	US$ 1.235 (319.21%)	511.7M
ELABElevai Labs Inc	US$ 0.0225 (1.81%)	290.23M
NVDANVIDIA Corporation	US$ 140.15 (-1.29%)	222.24M
SMCISuper Micro Computer Inc	US$ 21.54 (15.93%)	198.08M

tw0122

tw0122 4 months ago

LRMR above $9 momentarily

Monksdream

Monksdream 7 months ago

Monksdream

Monksdream 8 months ago

Monksdream

Monksdream 9 months ago

LRMR new 52 week high

Monksdream

Monksdream 9 months ago

LRMR new 52=week high

AJ Freely

AJ Freely 1 year ago

$LRMR - Announced that the FDA has cleared the Company’s four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601
👆Up 8% Pre-Market/ Current Price $3,40

magacrew2020

magacrew2020 2 years ago

could probably get through approval on just 25 mg if they are going to approve reta

subslover

subslover 2 years ago

The company said it received feedback from the FDA on information needed to resolve CTI-1601's current clinical hold, as well as a proposed change for a second phase. CTI-1601 is a treatment for Friedreich's ataxia.

Larimer plans to submit a complete response to CTI-1601's clinical hold in the third quarter.

Larimar is also proposing a phase two, four-week dose exploration study in Friedreich's ataxia patients. Friedreich's ataxia is a rare disease that causes progressive nervous system damage and movement problems, usually beginning during childhood.

JJJ54

JJJ54 3 years ago

I voted NO on the 2022 Annual Meeting Vote. I recommend you do the same.

DarkPool

DarkPool 3 years ago

oxnous

oxnous 4 years ago

Waking up . But volume should be higher.

DewDiligence

DewDiligence 4 years ago

LRMR 2Q20 results—6/30/20 cash=$113.7M:

https://www.globenewswire.com/news-release/2020/08/11/2076240/0/en/Larimar-Therapeutics-Reports-Second-Quarter-2020-Operating-and-Financial-Results.html

No CC.

casenumber

casenumber 4 years ago

Large chunks are being gobbled
Whales are lurking around?

subslover

subslover 4 years ago

The company they are merging with looks pretty darn impressive
https://chondrialtherapeutics.com/

casenumber

casenumber 5 years ago

ClayTrader

ClayTrader 5 years ago

* * $ZFGN Video Chart 12-26-2019 * *

Link to Video - click here to watch the technical chart video

ClayTrader

ClayTrader 5 years ago

* * $ZFGN Video Chart 12-24-2019 * *

Link to Video - click here to watch the technical chart video

whytestocks

whytestocks 5 years ago

News: $ZFGN Penny Stocks To Buy Or Sell Before The End Of 2019?

These Penny Stocks Moved Big But Can They Continue Higher Before Next Year? Over the course of the year, plenty of penny stocks have generated significant gains for investors. Even as the year comes to a close, there are some penny stocks that are gaining momentum. It is often said that inve...

Got this from ZFGN - Penny Stocks To Buy Or Sell Before The End Of 2019?

Fat Thor

Fat Thor 5 years ago

Like I said at .67 cents

ClayTrader

ClayTrader 5 years ago

* * $ZFGN Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

casenumber

casenumber 5 years ago

Wow...guess they will satisfy the 1dollar minimum nasd requirement with out rs.....
This will be huge when ticker change and merger consummated next month!

Scrap the notice of delisting boys.....

82M cash and 30M OS....sounds fun!

ClayTrader

ClayTrader 5 years ago

* * $ZFGN Video Chart 12-20-2019 * *

Link to Video - click here to watch the technical chart video

casenumber

casenumber 5 years ago

Over a buck soon when ticker change completed....

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

exactly is great

Fat Thor

Fat Thor 5 years ago

Probably 3-9 months away still - appears to be a massive over correction and tax loss selling on the merger news. Just a short target at the moment. They will run this in Q1 pre-split to get a much more favorable ratio IMO. Let's see what happens. Lots of cash on hand here at very low burn rate per Q.

The transaction is expected to close in the first half of 2020, subject to approvals by stockholders of each company and other customary closing conditions.

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

R/Split coming per 8k today

Fat Thor

Fat Thor 5 years ago

December discounts. With 85 million in cash, a merger, and priced at 67 cents there's no way this doesn't run soon. 35 million O/S.

casenumber

casenumber 5 years ago

Ticker change coming...Shorts will get burn if they will not cover or do damage control.
ZFGN has 82M dollars in cash!

The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.

casenumber

casenumber 5 years ago

Shorts covering.. they have to before it gets out of control once the merger is official...

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

10 day MA live chart huge oversold,safe here now,will recover nice

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

bought 3k at 6391

Fat Thor

Fat Thor 5 years ago

Just saw a bunch come through on tape that were vastly different but didn't indicate "out of sequence"...they were either out of sequence or it was a messed up market order. Just odd. This one is clearly under short attack. Volume could squeeze it near term.

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

ZFGN~~Balance Sheet
Total Cash (mrq) 82.01M
Total Cash Per Share (mrq) 2.19
Total Debt (mrq) 24.35M
Total Debt/Equity (mrq) 40.67
Current Ratio (mrq) 5.11
Book Value Per Share (mrq) 1.60
https://finance.yahoo.com/quote/ZFGN/key-statistics?p=ZFGN

alchemytrader

alchemytrader 5 years ago

not really. that would mean its been up and down, up and down. this is nothing but down..

Fat Thor

Fat Thor 5 years ago

...this price action is ALL over the place. Crazy.

alchemytrader

alchemytrader 5 years ago

man i hope so. just want out even now

BoilerRoom

BoilerRoom 5 years ago

$ZFGN in at .70

BoilerRoom

BoilerRoom 5 years ago

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

will recover but sucks,waste of time

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m.,

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

Conference Call Information
Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m., Eastern Time, to discuss the merger as well as other forward-looking information. Investors and other interested parties may participate by dialing (844) 824-7428 in the United States or (973) 500-2177 outside the United States and referencing conference ID number 5688136. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 11:30 a.m. ET on December 18, 2019 through December 25, 2019 by dialing (855) 859-2056 in the United States or (404) 537-3406 outside the United States. To access the replay please provide Conference ID number 5688136.

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

Widowsson32

Widowsson32 5 years ago

This is done no benefit to this company but ONTX will make you very rich

alchemytrader

alchemytrader 5 years ago

institutions selling off?

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

the news is great,why?

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

fffffffffffffffffff MMS

alchemytrader

alchemytrader 5 years ago

i guess were screwed

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 5 years ago

what the heck is going on here?

Larimar Therapeutics

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions